Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 4, 2022
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
[ Wed, May 04th 2022
] - WOPRAI
David Amsellem Downgraded (TEVA) to Sell and Decreased Target to $7 on, May 4th, 2022
David Amsellem of Piper Sandler, Downgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Sell and Decreased Target from $11 to $7 on, May 4th, 2022.
David has made no other calls on TEVA in the last 4 months.
There are 2 other peers that have a rating on TEVA. Out of the 2 peers that are also analyzing TEVA, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Thursday, January 27th, 2022
This is the rating of the analyst that currently disagrees with David
- Balaji Prasad of "Barclays" Upgraded from Hold to Buy and Increased Target to $13 on, Tuesday, April 5th, 2022
